Patents Assigned to TetraLogic Birinapant UK Ltd.
-
Patent number: 10034912Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.Type: GrantFiled: November 7, 2016Date of Patent: July 31, 2018Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
-
Patent number: 9920093Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: August 17, 2016Date of Patent: March 20, 2018Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Patent number: 9840464Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.Type: GrantFiled: June 15, 2016Date of Patent: December 12, 2017Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Patent number: 9394249Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.Type: GrantFiled: July 16, 2014Date of Patent: July 19, 2016Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Publication number: 20160052965Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: ApplicationFiled: October 15, 2015Publication date: February 25, 2016Applicant: TETRALOGIC BIRINAPANT UK LTD.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Patent number: 9187490Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: July 21, 2014Date of Patent: November 17, 2015Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin